NewAmsterdam Pharma had its Relative Strength (RS) Rating upgraded from 86 to 92 Thursday.
This exclusive rating from Investor's Business Daily identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks holds up against all the other stocks in our database.
History shows that the market's biggest winners often have an 80 or higher RS Rating as they begin their largest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
NewAmsterdam Pharma is building a cup without handle with a 27.29 buy point. See if the stock can break out in heavy volume.
The company showed 0% EPS growth last quarter. Sales increased 1,385%.
The company holds the No. 36 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and Halozyme Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
